Key Developments: MediciNova Inc (MNOV.W)
3.55USD
17 May 2013
$-0.48 (-11.91%)
$4.03
$3.55
$3.55
$3.55
300
114
$4.03
$1.62
Latest Key Developments (Source: Significant Developments)
Medicinova Inc Announces Completion of Payment to Private Placement
Medicinova Inc announced that the payment to the Company's private placement of 1,158,730 new shares to Samurai Investments San Diego LLC and Fountain Erika LLC has been completed on May 13, 2013 (United States time). The Company issued the new shares at USD 3.15 per share, or for USD 3,650,000 in total. Full Article
Medicinova Inc to Issue New Shares to Samurai Investments San Diego LLC and Fountain Erika LLC
Medicinova Inc announced that it has issued 1,000,000 shares to Samurai Investments San Diego LLC, as well as 158,730 shares to Fountain Erika LLC, at the price of USD 3.15 per share, or USD 3,650,000 in total, on May 13, 2013 (US time). Full Article
Medicinova Inc Lowers Consolidated Mid-year Outlook for FY 2013
Medicinova Inc announced that it has lowered its consolidated mid-year outlook for revenue from USD 650,000 to USD 3,257, operating profit from a loss of USD 4,856,000 to a loss of USD 5,147,000, ordinary profit from a loss of USD 4,856,000 to a loss of USD 5,149,000 and net profit from a loss of USD 4,856,000 to a los of USD 5,149,000, but raised the outlook for earning per share from a loss of USD 0.27 to a loss of USD 0.26, for the fiscal year ending December 2013. Full Article
Medicinova Inc to Issue New Shares to Macquarie Capital (USA) Inc.
Medicinova Inc to announced that it has decided to issue new shares of USD 6 million in total to Macquarie Capital (USA) Inc. The number and price of newly issued shares, as well as the issuing period are not decided. The Company will be using the proceeds on the development of medicine and other businesses. Full Article
Medicinova Inc Announces FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence
Medicinova Inc announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-166 (ibudilast) for the treatment of methamphetamine dependence. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious diseases and have the potential to fill an unmet medical need. An important feature of the FDA's Fast Track program is that it emphasizes early and frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Full Article
Medicinova Inc Receives Patent for MN-221
Medicinova Inc announced that it has received a patent for MN-221 in the Unites States. Full Article
Medicinova Inc Announces Initiation of Clinical Trial of MN-166 in Opioid Abusers With Columbia University and New York State Psychiatric Institute
Medicinova Inc announced the initiation of enrollment of a Phase 2a clinical trial with MN-166 (ibudilast) in prescription opioid or heroin abusers. The trial will be conducted at Columbia University and the New York State Psychiatric Institute and is funded by the National Institutes for Drug Abuse (NIDA), part of the National Institutes of Health. The MN-166 Phase 2a trial signifies the next step in the development of MN-166 and is the second of a strategic set of trials assessing the potential for MN-166 in opioid abuse and withdrawal. MN-166 is also in a Phase 2 trial for methamphetamine addiction at UCLA and will soon begin a separate Phase 2 trial for patients with multiple sclerosis. The NIDA-supported trial will enroll 24 healthy abusers of prescription opioids (including OxyContin, Vicodin, Percocet) or heroin. The goal of the trial is to assess MN-166's ability to not only reduce withdrawal symptoms following opioid detoxification, but to reduce the tendency to self-administer oxycodone, a frequently prescribed and abused opioid, and improve the acute pain relief action of oxycodone. The clinical trial subjects will complete two 20-day periods in a clinical research unit wherein they are detoxified and randomized to placebo or 100mg/day ibudilast (MN-166). Full Article
Medicinova Inc Receives Approval of Patent for Ibudilast MN-166 in Europe
Medicinova Inc announced that it has received an approval of patent for ibudilast MN-166 from European Patent Office. Ibudilast MN-166 is used for neuropathic pain treatment. Full Article
Medicinova Inc Announces Changes on Treasury Stock Distribution
Medicinova Inc announced that it will be selling 19,864 shares of its treasury stock, for USD 30,789.20 in total, instead of 19,543 shares for USD 30,291.65 in total. This was previously disclosed on October 1, 2012. The Company will be selling the treasury stock at the price of USD 1.55 per share on October 1, 2012. Full Article
Medicinova Inc Announces NIH Funds UCLA Phase 2 Study of MediciNova's MN-166 in Treating Drug Addiction
Medicinova Inc announced that it has received the approval and funding by the National Institutes on Drug Abuse (NIDA), part of the National Institutes of Health, of a Phase 2 clinical trial studying the use of MN-166 (ibudilast) for the treatment of methamphetamine addiction. Building on an ongoing UCLA MN-166 Phase 1b safety trial, NIDA has awarded grant funding for a statistically powered Phase 2 outpatient study in methamphetamine addicts. MediciNova will provide drug supply and regulatory support for the Phase 2 trial. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
